 |
17 Diseases |  |
0 Trials |
|
0 Trials |  |
21 News |  |
- || samatasvir (IDX719) / Merck (MSD)
Trial primary completion date: Study of Hepatitis C Virus (HCV) Nonstructural Protein 5a (NS5A) Inhibitor IDX719 in Healthy and HCV-Infected Participants (MK-1894-001) (clinicaltrials.gov) - Apr 27, 2015
P1/2, N=130, Completed, Sponsor: Merck Sharp & Dohme Corp.
Trial primary completion date: Apr 2012 --> Jul 2012
- |||| samatasvir (IDX719) / Merck (MSD)
Trial completion: Samatasvir (IDX719) in Combinations With Simeprevir and/or TMC647055/Ritonavir With or Without Ribavirin for 12 Weeks in Participants With Chronic Hepatitis C Infection (MK-1894-005) (clinicaltrials.gov) - Apr 23, 2015
P2, N=143, Completed, Sponsor: Merck Sharp & Dohme Corp.
Trial primary completion date: Apr 2012 --> Jul 2012 Active, not recruiting --> Completed
- || samatasvir (IDX719) / Merck (MSD)
Trial primary completion date: Samatasvir (IDX719) in Combinations With Simeprevir and/or TMC647055/Ritonavir With or Without Ribavirin for 12 Weeks in Participants With Chronic Hepatitis C Infection (MK-1894-005) (clinicaltrials.gov) - Mar 3, 2015
P2, N=143, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed Trial primary completion date: Jun 2014 --> Apr 2015
- | samatasvir (IDX719) / Merck (MSD)
Trial completion: Drug-Drug Interaction Between IDX719, Simeprevir, TMC647055 and Ritonavir When Administered in Combination in Healthy Participants (MK-1894-007) (clinicaltrials.gov) - Aug 29, 2014
P1, N=34, Completed, Sponsor: Idenix Pharmaceuticals
Trial primary completion date: Jun 2014 --> Apr 2015 Active, not recruiting --> Completed
- | samatasvir (IDX719) / Merck (MSD)
Trial completion, Trial primary completion date: Study to Evaluate Drug-Drug Interaction Between IDX719 and Simeprevir in Healthy Participants (MK-1894-004) (clinicaltrials.gov) - Aug 29, 2014
P1, N=42, Completed, Sponsor: Idenix Pharmaceuticals
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Apr 2013 --> Jul 2013
- | samatasvir (IDX719) / Merck (MSD)
Trial completion: To Evaluate the Effect of Ritonavir or Omeprazole on the Pharmacokinetics of Samatasvir (IDX719) in Healthy Participants (MK-1894-006) (clinicaltrials.gov) - Jul 21, 2014
P1, N=24, Completed, Sponsor: Idenix Pharmaceuticals
Active, not recruiting --> Completed | Trial primary completion date: Apr 2013 --> Jul 2013 Active, not recruiting --> Completed
- | samatasvir (IDX719) / Merck (MSD)
Trial completion: Pharmacokinetics of IDX719 in Participants With Normal and Impaired Hepatic Function (MK-1894-008) (clinicaltrials.gov) - Mar 11, 2014
P1, N=36, Completed, Sponsor: Idenix Pharmaceuticals
Active, not recruiting --> Completed Not yet recruiting --> Completed
- ||| samatasvir (IDX719) / Merck (MSD)
Enrollment closed: Samatasvir (IDX719) in Combinations With Simeprevir and/or TMC647055/Ritonavir With or Without Ribavirin for 12 Weeks in Participants With Chronic Hepatitis C Infection (MK-1894-005) (clinicaltrials.gov) - Jan 15, 2014
P2, N=143, Active, not recruiting, Sponsor: Idenix Pharmaceuticals
Not yet recruiting --> Completed Recruiting --> Active, not recruiting
- ||| samatasvir (IDX719) / Merck (MSD)
Enrollment change: Samatasvir (IDX719) in Combinations With Simeprevir and/or TMC647055/Ritonavir With or Without Ribavirin for 12 Weeks in Participants With Chronic Hepatitis C Infection (MK-1894-005) (clinicaltrials.gov) - Dec 3, 2013
P2, N=143, Active, not recruiting, Sponsor: Idenix Pharmaceuticals
Recruiting --> Active, not recruiting N=90 --> 143
- samatasvir (IDX719) / Merck (MSD)
Enrollment closed: Drug-Drug Interaction Between IDX719, Simeprevir, TMC647055 and Ritonavir When Administered in Combination in Healthy Participants (MK-1894-007) (clinicaltrials.gov) - Aug 7, 2013
P1, N=32, Active, not recruiting, Sponsor: Idenix Pharmaceuticals
N=90 --> 143 Recruiting --> Active, not recruiting
- | samatasvir (IDX719) / Merck (MSD)
New P1 trial: Pharmacokinetics of IDX719 in Participants With Normal and Impaired Hepatic Function (MK-1894-008) (clinicaltrials.gov) - Aug 6, 2013
P1, N=36, Completed, Sponsor: Idenix Pharmaceuticals
- | samatasvir (IDX719) / Merck (MSD)
New P1 trial: Drug-Drug Interaction Between IDX719, Simeprevir, TMC647055 and Ritonavir When Administered in Combination in Healthy Participants (MK-1894-007) (clinicaltrials.gov) - Jul 23, 2013
P1, N=32, Active, not recruiting, Sponsor: Idenix Pharmaceuticals
- ||||| samatasvir (IDX719) / Merck (MSD)
New P2 trial: Samatasvir (IDX719) in Combinations With Simeprevir and/or TMC647055/Ritonavir With or Without Ribavirin for 12 Weeks in Participants With Chronic Hepatitis C Infection (MK-1894-005) (clinicaltrials.gov) - May 12, 2013
P2, N=143, Active, not recruiting, Sponsor: Idenix Pharmaceuticals
- samatasvir (IDX719) / Merck (MSD)
Enrollment closed: To Evaluate the Effect of Ritonavir or Omeprazole on the Pharmacokinetics of Samatasvir (IDX719) in Healthy Participants (MK-1894-006) (clinicaltrials.gov) - Mar 25, 2013
P1, N=24, Active, not recruiting, Sponsor: Idenix Pharmaceuticals
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- samatasvir (IDX719) / Merck (MSD)
Enrollment closed: Study to Evaluate Drug-Drug Interaction Between IDX719 and Simeprevir in Healthy Participants (MK-1894-004) (clinicaltrials.gov) - Mar 25, 2013
P1, N=40, Active, not recruiting, Sponsor: Idenix Pharmaceuticals
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | samatasvir (IDX719) / Merck (MSD)
New P1 trial: To Evaluate the Effect of Ritonavir or Omeprazole on the Pharmacokinetics of Samatasvir (IDX719) in Healthy Participants (MK-1894-006) (clinicaltrials.gov) - Mar 17, 2013
P1, N=24, Active, not recruiting, Sponsor: Idenix Pharmaceuticals
- | samatasvir (IDX719) / Merck (MSD)
New P1 trial: Study to Evaluate Drug-Drug Interaction Between IDX719 and Simeprevir in Healthy Participants (MK-1894-004) (clinicaltrials.gov) - Mar 17, 2013
P1, N=40, Active, not recruiting, Sponsor: Idenix Pharmaceuticals
- ||| samatasvir (IDX719) / Merck (MSD)
Enrollment change: Study of Hepatitis C Virus (HCV) Nonstructural Protein 5a (NS5A) Inhibitor IDX719 in Healthy and HCV-Infected Participants (MK-1894-001) (clinicaltrials.gov) - Jul 11, 2012
P1/2, N=130, Completed, Sponsor: Idenix Pharmaceuticals
Recruiting --> Active, not recruiting N=60 --> 130
- |||| samatasvir (IDX719) / Merck (MSD)
Trial completion: Study of Hepatitis C Virus (HCV) Nonstructural Protein 5a (NS5A) Inhibitor IDX719 in Healthy and HCV-Infected Participants (MK-1894-001) (clinicaltrials.gov) - Jul 11, 2012
P1/2, N=130, Completed, Sponsor: Idenix Pharmaceuticals
N=60 --> 130 Recruiting --> Completed
- ||||| samatasvir (IDX719) / Merck (MSD)
New P1/2 trial: Study of Hepatitis C Virus (HCV) Nonstructural Protein 5a (NS5A) Inhibitor IDX719 in Healthy and HCV-Infected Participants (MK-1894-001) (clinicaltrials.gov) - Jan 9, 2012
P1/2, N=130, Completed, Sponsor: Idenix Pharmaceuticals